College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors

Report of the Prostate Cancer Working Group

David Grignon, E. H. Hammond

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Critical analysis of the evidence supporting the use of prognostic markers is needed for these to be used most appropriately in patient management. The College of American Pathologists recently sponsored a national conference to review the status of tumor markers for carcinomas of the breast, colon, and prostate gland. The conclusions of the Prostate Cancer Working Group are presented in this report. Currently, the TNM (Tumor, Lymph Node, Metastasis) staging system, histologic grading (Gleason system), and serum prostate- specific antigen are recommended for general use as prognostic markers in prostate cancer. Data support the use of DNA ploidy analysis in specific clinical settings, although general use is not currently recommended. The Working Group concluded that other markers do not have sufficient support in the literature to recommend routine use at the present time.

Original languageEnglish (US)
Pages (from-to)1122-1126
Number of pages5
JournalArchives of Pathology and Laboratory Medicine
Volume119
Issue number12
StatePublished - 1995
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Neoplasm Grading
Ploidies
Prostate-Specific Antigen
Tumor Biomarkers
Prostate
Neoplasms
Colon
Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis
DNA
Serum
Pathologists

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

@article{05bc0026de8b4a798a0eb48813a70fae,
title = "College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors: Report of the Prostate Cancer Working Group",
abstract = "Critical analysis of the evidence supporting the use of prognostic markers is needed for these to be used most appropriately in patient management. The College of American Pathologists recently sponsored a national conference to review the status of tumor markers for carcinomas of the breast, colon, and prostate gland. The conclusions of the Prostate Cancer Working Group are presented in this report. Currently, the TNM (Tumor, Lymph Node, Metastasis) staging system, histologic grading (Gleason system), and serum prostate- specific antigen are recommended for general use as prognostic markers in prostate cancer. Data support the use of DNA ploidy analysis in specific clinical settings, although general use is not currently recommended. The Working Group concluded that other markers do not have sufficient support in the literature to recommend routine use at the present time.",
author = "David Grignon and Hammond, {E. H.}",
year = "1995",
language = "English (US)",
volume = "119",
pages = "1122--1126",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "12",

}

TY - JOUR

T1 - College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors

T2 - Report of the Prostate Cancer Working Group

AU - Grignon, David

AU - Hammond, E. H.

PY - 1995

Y1 - 1995

N2 - Critical analysis of the evidence supporting the use of prognostic markers is needed for these to be used most appropriately in patient management. The College of American Pathologists recently sponsored a national conference to review the status of tumor markers for carcinomas of the breast, colon, and prostate gland. The conclusions of the Prostate Cancer Working Group are presented in this report. Currently, the TNM (Tumor, Lymph Node, Metastasis) staging system, histologic grading (Gleason system), and serum prostate- specific antigen are recommended for general use as prognostic markers in prostate cancer. Data support the use of DNA ploidy analysis in specific clinical settings, although general use is not currently recommended. The Working Group concluded that other markers do not have sufficient support in the literature to recommend routine use at the present time.

AB - Critical analysis of the evidence supporting the use of prognostic markers is needed for these to be used most appropriately in patient management. The College of American Pathologists recently sponsored a national conference to review the status of tumor markers for carcinomas of the breast, colon, and prostate gland. The conclusions of the Prostate Cancer Working Group are presented in this report. Currently, the TNM (Tumor, Lymph Node, Metastasis) staging system, histologic grading (Gleason system), and serum prostate- specific antigen are recommended for general use as prognostic markers in prostate cancer. Data support the use of DNA ploidy analysis in specific clinical settings, although general use is not currently recommended. The Working Group concluded that other markers do not have sufficient support in the literature to recommend routine use at the present time.

UR - http://www.scopus.com/inward/record.url?scp=0029617845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029617845&partnerID=8YFLogxK

M3 - Article

VL - 119

SP - 1122

EP - 1126

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 12

ER -